[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"depression-postpartum\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:depression-postpartum":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,52,77,103,127,149,176,197,240,267,294],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":4},"100640472","bed-rest-with-a-short-cervix-on-preterm-birth-100640472",false,"NCT07577388","Bed Rest With a Short Cervix on Preterm Birth","BEWISE - Bed Rest With a Short Cervix on Preterm Birth","BEWISE","Pregnant women with gestational age 20+0 to 33+6\n\n* Cervical length \\\u003C 25 mm in singleton pregnancies and \\\u003C 30 mm in multiple pregnancies\n* Above 18 years of age\n* Reads and understands Danish or English","FEMALE","18 Years",{"count":20,"type":21},6000,"ESTIMATED","INTERVENTIONAL",[24],"NA","Maternal AR has long been used to prevent PTB. However, definitions of AR vary widely, ranging from complete bed rest to partial limitation of physical activity for one or more hours daily.\n\nThe use of maternal AR to prevent preterm birth is largely based on observational evidence linking strenuous physical activity to an increased risk of preterm birth, and the assumption that reduced activity may decrease myometrial activity. However, the existing evidence on the clinical effects of AR remains limited and has not demonstrated a reduction in preterm birth or a delay in deliv-ery. In contrast, some studies suggest a potential increase in preterm birth following AR and instead significant adverse maternal and fetal effects.\n\nThe overall aim of this study is to compare gestational age at birth in women with a short cervix who are prescribed AR compared with women with a short cervix who are not prescribed AR (NAR).\n\nThe primary hypothesis is that NAR is non-inferior to AR in prolonging pregnancy in women with a short cervix.\n\nSecondary hypotheses are that, compared with AR, NAR is associated with higher level of physical activity, lower risk of maternal depression, and reduced risk of loss of maternal bone mineral density.\n\nThrough the BEWISE study, we wish to implement a change in the Danish national clinical practice regarding AR from recommending AR in risk groups (current practice) to no longer recommending AR as part as routine care (new practice). We will evaluate this change in clinical practice by prospectively collecting data from women both before and after implementation of the new recommendation. The transition from AR to NAR will be implemented sequentially in each Danish region using a randomised stepped-wedge (SW) cluster design, with each region constituting a cluster. The order in which regions transition is determined by randomisation. Each region will adopt the new recommendation at 3-month intervals, resulting in full national transition from AR to NAR within 12 months Eligible participants are pregnant women in gestational age 20+0 to 33+6 and cervical length \\\u003C 25 mm in singleton pregnancies and \\\u003C 30 mm in multiple pregnancies. Participants must be above 18 years of age and be able to read and understand Danish or English. There are no exclusion criteria.\n\nThe primary outcome is gestational age in days (continuous).",[27,28,29,30,31,32,33,34,35,36,37,38,39],"Preterm Birth","Cervical Insufficiency","Bed Rest","Pregnancy Complications","Immobilization","Depression, Postpartum","Pregnancy Outcome","Infant, Premature","Uterine Cervical Incompetence","Premature Birth","Obstetric Labor, Premature","Physical Activity","Bone Density","NOT_YET_RECRUITING","2026-05-03",{"date":43,"type":44},"2026-05-11","ACTUAL",{"date":46,"type":21},"2026-05-01",{"date":48,"type":21},"2029-05-01",{"name":50,"class":51},"Julie Glavind","OTHER",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100570090","enhanced-problem-solving-therapy-and-hiv-engagement-support-to-improve-perinatal-mental-health--hiv-outcomes-in-malawi-100570090","NCT06702722","Enhanced Problem-solving Therapy and HIV Engagement Support to Improve Perinatal Mental Health & HIV Outcomes in Malawi","Enhanced Problem-solving Therapy and HIV Engagement Support to Improve Perinatal Mental Health and HIV Outcomes in Malawi: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Presenting for antenatal care at one of our 5 recruitment sites\n* ≥ 18 years of age\n* ≤ 34 weeks gestation\n* HIV-positive, based on medical records\n* Initiating, re-initiating, or on established ART during index pregnancy\n* Elevated depressive symptoms as indicated by a EPDS score ≥10. The EPDS is widely used to assess perinatal mood disorders that has been validated in perinatal populations in Malawi with this cut point to identify probable perinatal depression\n\nExclusion Criteria:\n\n* Suicidal ideation evaluated as acute risk.\n* Other health concerns requiring emergent response.",{"count":60,"type":21},400,[24],"The main objective of the proposed study is to evaluate the effectiveness of the Enhanced Friendship Bench intervention to improve perinatal depression, HIV care engagement, and infant health outcomes among pregnant women with HIV and depression in Malawi.",[64,65,32],"HIV","Depression","RECRUITING","2026-04-28",{"date":69,"type":44},"2026-04-29",{"date":71,"type":44},"2025-02-26",{"date":73,"type":21},"2028-06",{"name":75,"class":51},"University of North Carolina, Chapel Hill",5,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100583498","healing-at-home-20---enhanced-chat-tool-for-lowering-postpartum-depression-100583498","NCT06877104","Healing at Home 2.0 - Enhanced Chat Tool for Lowering Postpartum Depression","HEALED","Inclusion Criteria:\n\n* Postpartum patients who have delivered a singleton baby at or after 37w0d at the Hospital of the University of Pennsylvania\n* Self-identify as a person of color (listed on chart as non-White race and confirmed with patient)\n* Able to speak, read and write English\n* Age ≥18\n* Prenatal care at outpatient practice affiliated with the Hospital of the University of Pennsylvania\n* Completion of clinically administered EPDS during inpatient stay\n* Routine discharge timing, day 2 or more after vaginal delivery, day 3 or more after cesarean delivery\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Baby not discharged with mother at postpartum discharge\n* Does not have access to a mobile phone",{"count":85,"type":21},156,[24],"The purpose of the study is to determine if access to a text-message based holistic chatbot support program \"Healing at Home 2.0\" decreases depressive symptoms as measured by the Edinburgh Postnatal Depression Scale (EPDS) compared to usual postpartum care for patients of color.",[32,89],"Postpartum Care",[91,65,92,89],"Chat tool","Text message based program","2026-03-25",{"date":95,"type":44},"2026-03-27",{"date":97,"type":44},"2025-03-13",{"date":99,"type":21},"2026-11",{"name":101,"class":51},"University of Pennsylvania",1,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":111,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100575470","validation-of-the-french-version-of-the-edinburgh-postnatal-depression-scale-epds-postnatally-in-the-father-100575470","NCT06772701","Validation of the French Version of the Edinburgh Postnatal Depression Scale (EPDS) Postnatally in the Father","EPDS-PERE","Inclusion Criteria:\n\n* All fathers whose baby is 10 days old or less\n\nExclusion Criteria:\n\n* People with a poor understanding of spoken or written French\n* Minors\n* Persons under court protection, guardianship or curatorship",true,"MALE",{"count":113,"type":21},1000,[24],"In recent years, fatherhood has changed considerably. Fathers are now more involved during the perinatal period, with their partner but also in caring for the child. Investigators now know that this period is also a source of major psychological upheaval, identity crisis, apprehension and anxiety for men. These upheavals can lead to depression that must be detected and treated as early as possible. This is an easy screening to perform using the EPDS (Edinburgh Postnatal Depression Scale). Currently, the EPDS is the most widely used self-questionnaire to assess the risk of depression in women during the perinatal period. Indeed, it is systematically recommended in many countries. It is starting to be used for the same purpose in the perinatal period in men, although the scale has not been validated in a representative sample of men in the pre- or post-natal period.\n\nThe main objective is to validate the use of the EPDS scale as a screening tool for postnatal depression in a population of French fathers.\n\nThey complete the PH-Q9, EPDS and socio-demographic questionnaires online at inclusion and 6 to 8 weeks after the birth of their child. Fathers included at the maternity ward also too Mini International Neuropsychiatric Interview (MINI) at inclusion.",[32],"2026-01-19",{"date":119,"type":44},"2026-01-21",{"date":121,"type":44},"2024-07-11",{"date":123,"type":21},"2027-03-12",{"name":125,"class":51},"Groupe Hospitalier du Havre",2,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":102},"100535006","from-prevention-to-treatment-how-biological-rhythms-can-maintain-perinatal-mental-health-100535006","NCT06246214","From Prevention to Treatment: How Biological Rhythms Can Maintain Perinatal Mental Health","Innovations in Biological Rhythms in the Context of Mental Health: Effectiveness of New Technologies and Exposure to Different Lighting Patterns in Women During the Postpartum Period","Inclusion Criteria:\n\n* 4-6 weeks postpartum;\n* Postnatal depression confirmed through Edinburgh Postnatal Depression Scale (EPDS) \\> 10;\n* Mini-International Neuropsychiatric Interview (M.I.N.I.) positive for current depressive episode.\n\nExclusion Criteria:\n\n* Active suicidal ideation;\n* Psychotic symptoms;\n* Unstable general medical conditions that interfere with the acquisition of actigraphy;\n* Newborn with severe health conditions (hospitalization, care in the neonatal ICU).",{"count":135,"type":21},150,[24],"Depression and anxiety are significant public health issues during pregnancy and the postnatal period, particularly affecting those in developing countries. Disruptions in biological rhythms, sleep problems, and low exposure to daylight are associated with a higher risk of these mental health issues. The perinatal period poses unique challenges to the temporal program, with evidence indicating that sleep disturbances significantly increase the risk of postnatal depression. A Randomised Clinical Trial (RCT) is being conducted to assess the effectiveness of Blue Light Therapy (BlueLT) in treating depressive and anxiety symptoms during the postpartum. The RCT will also investigate the alignment of rest-activity and internal body time as mediating factors. This study will focus on various chronobiological factors, including rest-activity rhythms, light exposure levels, temperature rhythms, sleep duration and phase, social jetlag, and BodyTime (assessed through a single blood sample). The goal is to recruit 50 women with postpartum depression, with 25 in the BlueLT intervention group and 25 in the ControlLT placebo group, alongside 100 healthy controls. The BlueLT device uses a short-wavelength LED lamp mainly composed by a wavelength peak on blue spectrum, while the ControlLT device has a dim long-wavelength LED. A Healthy Control group will also be included to account for changes unrelated to depression diagnosis or placebo\u002Ftreatment effects. Exclusion criteria involve a history of major depressive or anxiety disorder, current psychotic disorder, night shift work, active suicidal thoughts, unstable medical conditions interfering with data collection, and newborns with severe health conditions. The study aims to evaluate the impact of BlueLT on postpartum depression and understand the role of chronobiological factors in the health\u002Fdisease process.",[32,139],"Anxiety State","2025-11-25",{"date":142,"type":44},"2025-12-03",{"date":144,"type":44},"2024-01-04",{"date":146,"type":21},"2027-05",{"name":148,"class":51},"Hospital de Clinicas de Porto Alegre",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":110,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":164,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":126},"100544100","trueblue-clinical-study---investigating-the-use-of-a-mobile-phone-app-trueblue-for-monitoring-depression-and-anxiety-100544100","NCT06364488","TrueBlue Clinical Study - Investigating the Use of a Mobile Phone App TrueBlue for Monitoring Depression and Anxiety","Inclusion Criteria:\n\n\\- 18 years or older\n\n* Fluent in spoken and written English\n* Has capacity to provide consent\n* At least 12 weeks pregnant or less than 12 weeks postpartum\n* Access to internet connectivity\n* Access to a compatible smart phone device (for up to 10 participants, where needed through not having a personal device, this access may be provided through the study team).\n* Has a current GP within Nottinghamshire\n\nExclusion Criteria:\n\n* ● Current clinically diagnosed psychiatric disorder other than depression\n\n  * Previous history of a clinically diagnosed psychiatric disorder, other than depression and generalised anxiety disorder (including previous Psychosis, Bipolar Disorder, Personality Disorder, Substance Abuse Disorders, Eating Disorders)\n  * Clinical diagnosis of an Autistic Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Parkinson's Disease or other current Neurological Disorder.",{"count":156,"type":21},125,[24],"This trial will assess the safety, feasibility, acceptability, usability and agreement with validated scales of an automated mood monitoring App (TrueBlue), in adult, perinatal participants (recruited between 12 weeks of pregnancy and 12 weeks post-partum), recruited across multiple sites in Nottinghamshire, United Kingdom (UK). An initial within-study pilot phase will assess key aspects of the study including recruitment rate, usability issues and a detailed understanding of any device related adverse events; prior to full recruitment of a total 125 participants over a total 14-month period.",[65,32,160,161,162,163],"Anxiety in Pregnancy","Anxiety","Anhedonia","Perinatal Depression",[65,161,165],"Perinatal","2025-09-16",{"date":168,"type":44},"2025-09-19",{"date":170,"type":44},"2024-10-01",{"date":172,"type":21},"2026-12-30",{"name":174,"class":175},"BlueSkeye AI","INDUSTRY",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":185,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":102},"100596619","a-study-to-learn-more-about-how-zuranolone-affects-postpartum-depression-symptoms-in-participants-who-took-it-within-1-year-after-the-end-of-their-pregnancy-100596619","NCT07047820","A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy","Prospective, Observational Survey Study Assessing Effectiveness of Zuranolone in Improving PPD Symptoms in the Real-world Setting","Key Inclusion Criteria:\n\n* Adults who were prescribed and had one successful fill for zuranolone within 12 months following end of pregnancy for the treatment of PPD from June 2025 to May 2026 through CVS Specialty Pharmacy.\n* Currently reside in the United States.\n* Able to complete the questionnaires independently.\n\nKey Exclusion Criteria:\n\n* Prior fill of zuranolone or brexanolone in last 12 months.\n* Participants with 2 or more doses of zuranolone at the time of screening.\n* Current or history of bipolar disorder.\n* Failure to complete baseline surveys prior to 2nd dose of zuranolone.\n* Pregnancy that ended more than 12 months ago.\n\nOther protocol-defined Inclusion\u002FExclusion criteria may apply.",{"count":184,"type":21},200,"OBSERVATIONAL","In this study, researchers will learn more about how zuranolone affects the symptoms of postpartum depression, also known as PPD. Zuranolone is a drug that healthcare professionals can prescribe for adults with PPD. After giving birth, adults with PPD can suffer from symptoms such as tiredness, sadness, and a loss of interest in their daily activities.\n\nThis study is known as an observational study, which means it collects health information about study participants after a healthcare professional has already prescribed treatment. Participants for this study will be found in the United States using a database from CVS Specialty Pharmacy. This will include anyone who was prescribed zuranolone between June 2025 and May 2026 and who filled the prescription within 1 year after the end of their pregnancy.\n\nThe main goal of this study is to learn more about how zuranolone affects the participants' PPD symptoms. This will be measured using a questionnaire completed by participants called the Edinburgh Postnatal Depression Scale, also known as the EPDS. A higher score on the EPDS may indicate more severe PPD symptoms.\n\nThe main question researchers want to answer in this study is:\n\n\\- Do PPD symptoms change after treatment with zuranolone based on EPDS scores measured at Day 15?\n\nResearchers will also learn more about:\n\n* Changes in participants' EPDS scores from before treatment to Day 45, which is 30 days after treatment ends.\n* How many participants breastfeed their babies while taking zuranolone\n* How many participants do not start new medicine after finishing their zuranolone treatment\n* How many participants take new medicines after finishing zuranolone\n* How many participants already tried other medicines for their depression symptoms before joining this study\n* How many participants take other medicines in general while taking zuranolone\n\nThis study will be done as follows:\n\nPeople who fill their zuranolone prescription through CVS Specialty Pharmacy will be contacted by email or phone to ask them about their interest in participating in the study.\n\nThose who agree to take part will answer written questions about their symptoms using the EPDS tool. They will also answer other survey questions about their background, environment, and general health information. Participants must take their first dose of zuranolone within 7 days of joining the study.\n\nParticipants will then be asked to answer questions using the EPDS tools, 15 days and 45 days after taking the first dose of zuranolone.",[32],"2025-07-30",{"date":190,"type":44},"2025-08-03",{"date":192,"type":44},"2025-06-30",{"date":194,"type":21},"2026-08-24",{"name":196,"class":175},"Biogen",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":205,"minAge":18,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":208,"briefSummary":209,"conditions":210,"keywords":214,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":239},"100529540","heartgps-a-study-exploring-the-effects-of-a-psychological-intervention-for-parents-and-their-babies-after-prenatal-cardiac-diagnosis-100529540","NCT06175104","HeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis","HeartGPS: A Longitudinal Randomized Controlled Trial Examining the Effects of a Prenatally-Delivered Psychological Intervention for Parents and Their Babies With Single Ventricle Congenital Heart Disease","HeartGPS","Inclusion Criteria\n\n1. Pregnant person carrying a fetus diagnosed with single ventricle congenital heart disease (CHD).\n2. Single ventricle CHD diagnosis between 16 and 30 weeks gestation.\n3. Singleton pregnancy.\n4. Pregnant person is planning to continue with the pregnancy.\n5. Pregnant person is able to participate and complete study assessments in English.\n\nExclusion Criteria\n\n1. Fetus with comorbid condition with a predictable adverse impact on neurodevelopment (e.g., DiGeorge Syndrome).\n2. Fetal or maternal medical condition determined by treating physician to be contraindicative to study participation.\n3. Parent with an untreated major psychiatric condition, substance use disorder, or other circumstances that would interfere with study engagement or safe participation in the trial.\n4. Parent with a moderate to severe intellectual disability.\n5. Parent age \\\u003C18 years.\n6. Surrogate for pregnancy.\n\nPrenatal administration of oral or intravenous corticosteroids for fetal lung maturation will be recorded but are not a reason for exclusion.","ALL",{"count":207,"type":21},50,[24],"Babies with single ventricle congenital heart disease (SVCHD) are often diagnosed during pregnancy. While prenatal diagnosis has important clinical benefits, it is often stressful and overwhelming for parents, and many express a need for psychological support. HeartGPS is a psychological intervention for parents who receive their baby's diagnosis of SVCHD during pregnancy. It includes 8 sessions with a psychologist, coupled with tailored educational resources, and a personalized care plan. The intervention focuses on fostering parent psychological adjustment and wellbeing, and supporting parents to bond with their baby in ways that feel right for them. Through this study, the investigators will learn if HeartGPS is useful and effective for parents and their babies when it is offered in addition to usual fetal cardiac care. The investigators will examine the effects of the HeartGPS intervention on parental anxiety, depression, and traumatic stress; fetal and infant brain development; parent-infant bonding; and infant neurobehavioral and neurodevelopmental outcomes. The investigators will also explore mechanisms associated with stress biology during pregnancy, infant brain development and neurodevelopmental outcomes, and parent and infant intervention effects.",[211,160,32,212,213],"Heart Defects, Congenital","Trauma, Psychological","Neurodevelopmental Disorders",[215,216,217,218,219,220,221,222,223,224,225,226,227,228,229],"Congenital Heart Disease","Prenatal","Mental Health","Neurodevelopment","Neurobehavior","Fetal Cardiology","Psychological Intervention","Mother-Infant Attachment","Mother-Infant Bonding","Medical Traumatic Stress","Neuroimaging","Brain Development","Fetal Neuroimaging","Perinatal Mental Health","Medical Psychology","2025-07-16",{"date":232,"type":44},"2025-07-20",{"date":234,"type":21},"2025-07-14",{"date":236,"type":21},"2027-12",{"name":238,"class":51},"Children's Hospital Medical Center, Cincinnati",4,{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":252,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":126},"100555433","implementation-of-a-psychoeducational-intervention-in-new-mothers-100555433","NCT06512025","Implementation of a Psychoeducational Intervention in New Mothers","Adaptation and Implementation of a Psychoeducational Intervention to Prevent Postpartum Depression and Anxiety Disorders in New Mothers","EQEP","Inclusion Criteria:\n\n* Primiparous women\n* Given birth a healthy, full-term baby in the preceding 2 weeks\n* Receiving postpartum healthcare at Atenció a la salut sexual i reproductiva (ASSIR) of Àrea Integral de Salut Barcelona Esquerra (AIS-BE)\n* Over 18 years of age\n* Give consent to participate in the study\n\nExclusion Criteria:\n\n* If are unable to complete the questionnaires due to language or literacy barriers",{"count":60,"type":21},[24],"The goal of this clinical trial is to implement and examine the clinical effectiveness in a randomized study of the Catalan and Spanish versions of the culturally adapted \"What Were We Thinking (WWWT)\" psychoeducational intervention in primary care services, with the aim of preventing and reducing the prevalence of postpartum mental illness in new mothers. Additionally, the trial will assess the acceptability and accessibility of the intervention by families and professionals.\n\nResearchers will compare \"Usual Care\" (standard postnatal care provided by professionals from the Sexual and Reproductive Health Service) with \"Intervention group\" (usual care plus two psychoeducative intervention WWWT sessions) to see if the \"WWWT intervention\" is better than \"Usual Care\" at preventing postpartum depression and anxiety disorders in new mothers.\n\nParticipants will:\n\n* Take baseline questionnaires at 2-4 weeks postpartum\n* Take usual care or usual care plus two psychoeducative intervention WWWT sessions within the first 6 weeks postpartum\n* Take the same questionnaires used in baseline plus a semi-structured interview to diagnose major mental disorder (all participants) at 3 and 6 months follow-up\n* Take a brief anonymous self-report survey (only those participants taking the WWWT intervention)",[32,161],[253,254,255,256,257,258],"Postpartum Period","Prevention","Preventive Health Care","Psychoeducation","Primiparity","Female","2025-02-24",{"date":71,"type":44},{"date":262,"type":44},"2024-11-08",{"date":264,"type":21},"2027-06",{"name":266,"class":51},"Alba Roca",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":110,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":275,"targetDuration":277,"studyType":185,"phases":4,"briefSummary":278,"conditions":279,"keywords":284,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":292,"locationsCount":126},"100513118","diagnostic-accuracy-of-the-stepped-screening-protocol-and-its-screening-tools-in-the-perinatal-period-100513118","NCT05961306","Diagnostic Accuracy of the Stepped Screening Protocol and Its Screening Tools in the Perinatal Period.","Diagnostic Accuracy of the Stepped Screening Protocol and Its Screening Tools for Depression, Anxiety Disorders, Obsessive-compulsive Disorders and Posttraumatic Disorders in the Perinatal Period.","DAS","Inclusion Criteria:\n\n* 18 years or older, antenatal period (20-24 th week of pregnancy) or postnatal period (6 to 10 weeks after birth) and Dutch-speaking.\n\nExclusion Criteria:\n\n* \\\u003C18 years, non-Dutch speaking and outside the above mentioned period.",{"count":276,"type":21},1800,"2 Weeks","It is known that 1 in 5 women experience psychological difficulties during their pregnancy or in the first year after giving birth. Unfortunately, in 75% of cases, these problems go undetected, resulting in the woman, her partner and the baby not receiving the proper care. For this reason, the Flemish government wants to screen all women in the perinatal period for their mental well-being using short questionnaires with the aim of referring them to appropriate care. Before they can recommend this screening to all women in the perinatal period, it is necessary to investigate the effectiveness of these short questionnaires, as well as the proposed stepped screening protocol.\n\nThe investigators want to use this study to determine whether the questionnaires and the stepped screening protocol are sufficiently sensitive to detect mental health problems during this period. This means that they want to check whether the (future) moms who screen positive actually have problems and whether the (future) moms who screen negative effectively do not have psychological problems. In case of positive findings, teh investigators want to recommend that screening for psychological well-being should best be part of standard care in the future.\n\nParticipants will be asked to answer some questions regarding depressive and anxiety symptoms using existing screening instruments (Whooley, GAD-2, EPDS and GAD-7). On the basis of an online application one can be assigned to the group that will be invited for a telephone interview by a study employee of the UZ Gent (psychologist or psyciatrist) to conduct a semi-structured interview within 2 weeks after completing these questions. The interviewer will ask questions about current psychological well-being and, where applicable, psychological problems in the past. The interviewer will not be aware of the responses to the questionnaires, so as not to be prejudiced. Being contacted for an interview does not necessarily mean that those women scored higher on the questionnaires, as they may also belong to the control group.\n\nIn addition, a number of demographic data are requested (such as age, marital status, level of education, occupational category, how many pregnancies, number of other (living) children, (expected) delivery date, current forms of treatment (medications, psychotherapeutic interventions) and psychiatric history).",[280,32,281,282,283],"Depressive; Episode, Major","Anxiety Disorders","Obsessive-Compulsive Disorder","Posttraumatic Stress Disorder",[285],"diagnostic accuracy","2024-10-28",{"date":288,"type":44},"2024-10-30",{"date":290,"type":44},"2023-08-10",{"date":192,"type":21},{"name":293,"class":51},"University Hospital, Ghent",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":110,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":185,"phases":4,"briefSummary":302,"conditions":303,"keywords":304,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":102},"100552160","evaluation-of-access-to-screening-for-post-partum-depression-via-the-postnatal-interview-within-8-weeks-of-birth-in-women-who-have-gave-birth-at-the-troyes-hospital--depressionpp--100552160","NCT06469476","Evaluation of Access to Screening for Post-partum Depression Via the Postnatal Interview Within 8 Weeks of Birth in Women Who Have Gave Birth at the Troyes Hospital ( DEPRESSIONPP )","DEPRESSIONPP","Inclusion criteria:\n\n* The study will include adult women who have given birth at the Centre hospitalier de Troyes from July 2022 to October 2023\n* and agreeing to take part in the study.\n\nnon inclusion criteria\n\n* minors under the age of 18\n* those protected by law (guardianship, curatorship and safeguard of justice)\n* patients refusing to take part in the study",{"count":60,"type":21},"Post-partum depression is defined as a depressive disorder with onset of symptoms in the year following childbirth. Several international studies have reported a prevalence of this condition of around pathology of around 15%. Santé publique France's 2021 national perinatal survey corroborated these figures, finding a prevalence of post-partum depression in France of in France of 16.7%. It is therefore a frequent pathology that can cause complications for both mother and child.\n\nThe complications both for the mother and for the mother-child bond. Indeed, post-partum depression can lead to an increased risk of infanticide, weaker mother-child attachment, and altered parental behaviour. post-partum depression can lead to maternal suicide (the second leading cause cause of maternal mortality in France). Despite the potential seriousness of severe depression and its impact on the on the mother-child bond, just under half of those suffering from severe depression suffering from severe depression consult a healthcare professional.\n\nFear of being judged or stigmatised, linked to misperceptions about the episode, is one of the main obstacles to consultation.\n\nOf being judged or stigmatised, linked to erroneous representations of the depressive episode. Given the scale of this condition, and the difficulties young mothers face in seeking help for young mothers to seek help, it is vital to screen postpartum women as widely and post-partum women as early as possible. In view of the extent of this condition and the difficulties young mothers have in seeking help for young mothers, it is vital to screen post-partum women as widely and as post-partum. With this in mind, from July 2022, a compulsory early post-natal interview has been introduced, designed to screen for postpartum depression.",[32],[305],"depression post partum","2024-06-17",{"date":308,"type":44},"2024-06-21",{"date":310,"type":44},"2024-03-01",{"date":312,"type":21},"2024-08-31",{"name":314,"class":51},"Centre Hospitalier de Troyes"]